For people with HIV and belly fat who have high liver enzyme levels, those who lost at least 8% of their visceral fat from tesamorelin treatment had much bigger drops in their liver enzyme levels compared to those who didn't lose much fat.

For people with HIV and belly fat who have high liver enzyme levels, those who lost at least 8% of their visceral fat from the drug had much bigger drops in their liver enzyme numbers compared to those who didn't lose much fat, and this difference was statistically significant.

HIV patients with belly fat and high liver enzymes who lost at least 8% of their visceral fat from the drug saw their ALT drop by about 9 points (18%) and AST by 4 points (10%) after six months of treatment.

HIV patients with high liver enzymes who lost visceral fat from the drug kept their liver enzyme levels improved for a full year even after stopping the drug and some fat coming back.

For HIV patients with belly fat and high liver enzymes, taking a placebo even if they lost visceral fat didn't help lower their liver enzyme levels, unlike those taking the actual drug.

HIV patients with high liver enzymes who lost at least 8% visceral fat after taking tesamorelin saw their ALT drop by about 9 units on average, while those without fat loss had a slight increase, showing a clear benefit from fat reduction.